Press release from Companies

Published: 2020-02-06 15:26:14

WntResearch AB: WntResearch announces the Hungarian authority"s approval for the Company"s phase 2 study to commence

WntResearch has today received notice that the Hungarian authority has approved the Company"s application to start the NeoFox study in Hungary as well. The Hungarian contract research organization Optimapharm will now intensifty its efforts to conclude agreements with the 12 clinics that will participate in the study.

The application that was submitted to the authority on 18 December has been treated expeditiously, since adequate response has been given to the questions that were raised when the first application was rejected.

Since the application has been reviewed in a much shorter timeframe than initially communicated by the authority, the effort to finalize contracts with the Hungarian clinics has now been intensified. WntResearch"s goal is to activate the first clinics during the current month.

At present, 32 patients are included in the Spanish NeoFox study. All of the new clinics have now been activated, and three of them have included their first patients. The Company can not provide a new estimate of the patient recruitment rate at this time, as it awaits the initiation and progress in Hungary.

"We are very pleased with the Hungarian authority"s statement today. The fact that the response was received almost a month earlier than expected will result in an additional workload for our Hungarian partner Optimapharm, but that is a very positive development," says Peter Morsing, CEO of WntResearch.

For more information, please contact:

Peter Morsing, CEO, WntResearch AB
E-mail: pm@wntresearch.coman

Telephone: +46 727 200711

This information is information that WntResearch AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on February 6, 2020.

About WntResearch

WntResearch is developing an entirely new kind of cancer drug, which inhibits the tumour cells" ability to spread through the body and metastasize. The majority of cancer deaths are due to metastases, and there are no therapies available that can prevent that. Foxy-5, the Company"s most advanced drug candidate, is a peptide that mimics the body"s own WNT5A protein. In preclinical trials, Foxy-5 has demonstrated ability to suppress the mobility and invasive power of cancer cells, and thus to inhibit metastasis. Phase 1 studies on patients with colon, prostate and breast cancer have demonstrated a good safety profile and favourable pharmacokinetics, and early data indicates biological activity. A Phase 2 multicenter study is underway on patients with colon cancer, in order to study the anti-metastasizing efficacy of Foxy-5. WntResearch"s share is listed on Spotlight Stock Market. For more information, please visit: www.wntresearch.com

Läs mer hos Cision
Read more about WntResearch AB

Subscription